Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill targets brain tumor gene in early trial

NCT ID NCT04458272

First seen Apr 22, 2026 · Last updated May 20, 2026 · Updated 5 times

Summary

This study tests an experimental drug called DS-1001b in 25 people with a type of slow-growing brain tumor (grade II glioma) that has a specific IDH1 gene mutation. Participants have not had chemotherapy or radiation before. The goal is to see if the drug can shrink or control the tumor and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WHO GRADE II GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Kyorin University Hospital

    Tokyo, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Tokyo Women's Medical University Hospital

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.